HK1244004A1 - 内酰胺激酶抑制劑 - Google Patents
内酰胺激酶抑制劑Info
- Publication number
- HK1244004A1 HK1244004A1 HK18103455.2A HK18103455A HK1244004A1 HK 1244004 A1 HK1244004 A1 HK 1244004A1 HK 18103455 A HK18103455 A HK 18103455A HK 1244004 A1 HK1244004 A1 HK 1244004A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibitors
- lactam kinase
- lactam
- inhibitors
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261617657P | 2012-03-29 | 2012-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1244004A1 true HK1244004A1 (zh) | 2018-07-27 |
Family
ID=49261191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18103455.2A HK1244004A1 (zh) | 2012-03-29 | 2018-03-12 | 内酰胺激酶抑制劑 |
Country Status (6)
Country | Link |
---|---|
US (4) | US9260442B2 (zh) |
EP (2) | EP2831080B1 (zh) |
AU (1) | AU2013239816B2 (zh) |
CA (1) | CA2868966C (zh) |
HK (1) | HK1244004A1 (zh) |
WO (1) | WO2013148748A1 (zh) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
KR101929593B1 (ko) * | 2010-10-25 | 2018-12-14 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
AU2013239816B2 (en) | 2012-03-29 | 2017-08-24 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
CN104302620A (zh) | 2012-04-26 | 2015-01-21 | 弗朗西斯·泽维尔·塔瓦雷斯 | 内酰胺的合成 |
ME03557B (me) | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Privremena zaštiтa normalnih ćelija током hemoterapije |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
US9717735B2 (en) | 2014-04-17 | 2017-08-01 | G1 Therapeutics, Inc. | Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016203347A1 (en) * | 2015-06-17 | 2016-12-22 | Pfizer Inc. | Tricyclic compounds and their use as phosphodiesterase inhibitors |
US10112955B2 (en) | 2015-10-29 | 2018-10-30 | Effector Therapeutics, Inc. | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 |
JP6888006B2 (ja) | 2015-10-29 | 2021-06-16 | イーフェクター セラピューティクス, インコーポレイテッド | Mnk1およびmnk2を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物 |
US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
MX2019000200A (es) | 2016-07-01 | 2019-09-26 | G1 Therapeutics Inc | Agentes antiproliferativos basados en pirimidina. |
BR112018077155A2 (pt) | 2016-07-01 | 2019-04-02 | G1 Therapeutics, Inc. | processo para preparar um composto, e, composto |
WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
US11865176B2 (en) | 2016-11-08 | 2024-01-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
KR20190092478A (ko) | 2016-12-05 | 2019-08-07 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
BR112019013814A2 (pt) | 2017-01-06 | 2020-01-21 | G1 Therapeutics Inc | método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit. |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
JP2020507588A (ja) | 2017-02-14 | 2020-03-12 | イーフェクター セラピューティクス, インコーポレイテッド | ピぺリジン置換MnK阻害剤およびそれに関連する方法 |
US10578179B2 (en) * | 2017-04-26 | 2020-03-03 | Fox Factory, Inc. | Multi-mode air shock |
KR102659211B1 (ko) | 2017-06-29 | 2024-04-18 | 쥐원 쎄라퓨틱스, 인크. | G1t38의 형체 형태 및 그의 제조 방법 |
JP2021509680A (ja) | 2018-01-08 | 2021-04-01 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | G1t38の優れた投与レジメン |
CN112839657A (zh) | 2018-08-24 | 2021-05-25 | G1治疗公司 | 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成 |
JP2022505846A (ja) | 2018-10-24 | 2022-01-14 | イーフェクター セラピューティクス, インコーポレイテッド | Mnk阻害剤の結晶形態 |
WO2020206034A1 (en) * | 2019-04-01 | 2020-10-08 | G1 Therapeutics, Inc. | Cell cycle inhibiting compounds for the treatment of medical disorders |
JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置 |
AU2021273744A1 (en) | 2020-05-19 | 2022-12-08 | G1 Therapeutics, Inc. | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
TW202320795A (zh) | 2021-07-26 | 2023-06-01 | 美商凱爾科迪股份有限公司 | 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE391719T1 (de) | 1997-02-05 | 2008-04-15 | Warner Lambert Co | Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
MXPA03000068A (es) * | 2000-06-26 | 2003-09-25 | Pfizer Prod Inc | Compuestos de pirrolo (2,3-d)pirimidina como agentes inmunosupresores. |
DK1470124T3 (da) | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
MXPA06000484A (es) | 2003-07-11 | 2006-04-05 | Warner Lambert Co | Sal de isetionato de un inhibidor selectivo de la quinasa 4 dependiente de ciclina. |
EP1678177B1 (en) | 2003-10-23 | 2007-11-28 | F.Hoffmann-La Roche Ag | Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders |
GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
ES2411975T3 (es) | 2005-01-14 | 2013-07-09 | Janssen Pharmaceutica Nv | Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas |
CN101228161B (zh) * | 2005-05-20 | 2012-10-10 | 沃泰克斯药物股份有限公司 | 适用作蛋白激酶抑制剂的吡咯并吡啶类 |
US20070049591A1 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
ATE448230T1 (de) * | 2005-12-09 | 2009-11-15 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
MX2009013897A (es) | 2007-06-25 | 2010-03-30 | Neurogen Corp | Piperacinil oxoalquil tetrahidro-beta-carbolinas y analogos relacionados. |
WO2009085185A1 (en) * | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
CA2734802C (en) * | 2008-08-22 | 2016-05-31 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
WO2010039997A2 (en) | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
CN102231983A (zh) | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护 |
JP2012526850A (ja) | 2009-05-13 | 2012-11-01 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | サイクリン依存性キナーゼ阻害剤及びその用法 |
US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
KR101929593B1 (ko) * | 2010-10-25 | 2018-12-14 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
AU2013239816B2 (en) | 2012-03-29 | 2017-08-24 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
CN104302620A (zh) | 2012-04-26 | 2015-01-21 | 弗朗西斯·泽维尔·塔瓦雷斯 | 内酰胺的合成 |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
ME03557B (me) | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Privremena zaštiтa normalnih ćelija током hemoterapije |
US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
US9787460B2 (en) | 2015-07-16 | 2017-10-10 | LGS Innovations LLC | Self-interference channel estimation system and method |
-
2013
- 2013-03-27 AU AU2013239816A patent/AU2013239816B2/en not_active Ceased
- 2013-03-27 EP EP13770192.6A patent/EP2831080B1/en not_active Not-in-force
- 2013-03-27 CA CA2868966A patent/CA2868966C/en not_active Expired - Fee Related
- 2013-03-27 WO PCT/US2013/033971 patent/WO2013148748A1/en active Application Filing
- 2013-03-27 EP EP17155466.0A patent/EP3216792B1/en active Active
-
2014
- 2014-09-26 US US14/498,796 patent/US9260442B2/en active Active
-
2015
- 2015-12-29 US US14/982,443 patent/US9745316B2/en active Active
-
2016
- 2016-11-10 US US15/348,862 patent/US9856268B2/en active Active
-
2018
- 2018-01-02 US US15/860,483 patent/US10464940B2/en active Active
- 2018-03-12 HK HK18103455.2A patent/HK1244004A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20160108054A1 (en) | 2016-04-21 |
US9856268B2 (en) | 2018-01-02 |
EP3216792B1 (en) | 2020-05-27 |
WO2013148748A1 (en) | 2013-10-03 |
AU2013239816A1 (en) | 2014-10-30 |
EP2831080B1 (en) | 2017-03-15 |
US10464940B2 (en) | 2019-11-05 |
US20170057972A1 (en) | 2017-03-02 |
US9745316B2 (en) | 2017-08-29 |
EP2831080A1 (en) | 2015-02-04 |
CA2868966C (en) | 2021-01-26 |
CA2868966A1 (en) | 2013-10-03 |
US20150018348A1 (en) | 2015-01-15 |
US9260442B2 (en) | 2016-02-16 |
AU2013239816B2 (en) | 2017-08-24 |
EP3216792A1 (en) | 2017-09-13 |
US20180127431A1 (en) | 2018-05-10 |
EP2831080A4 (en) | 2015-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244004A1 (zh) | 内酰胺激酶抑制劑 | |
HK1210775A1 (zh) | 作為激酶抑制劑的咪唑並三嗪甲腈 | |
HK1208442A1 (zh) | 作為 激酶抑制劑的取代的吡咯並嘧啶基氨基-苯並噻唑酮 | |
HK1215577A1 (zh) | 蛋白激酶抑制劑 | |
LT2903618T (lt) | Rho kinazės inhibitoriai | |
HK1212683A1 (zh) | 多個激酶途徑抑制劑 | |
HK1222647A1 (zh) | 激酶抑制劑 | |
HUE048834T2 (hu) | Kináz inhibitorok | |
EP2917210A4 (en) | KINASE INHIBITORS | |
HK1209277A1 (zh) | -三嗪- -甲酰胺激酶抑制劑 | |
IL229028A0 (en) | Kinase inhibitors | |
PL2634185T3 (pl) | Inhibitory kinazy TYK2 | |
HK1209726A1 (zh) | 蛋白激酶抑制劑 | |
HK1199873A1 (zh) | 激酶抑制劑 | |
HK1213252A1 (zh) | 雙環二氫吡啶酮激酶抑制劑 | |
HK1205506A1 (zh) | 炔類化合物的蛋白激酶抑制劑 | |
SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
HK1208460A1 (zh) | 蛋白激酶抑制劑 | |
HK1209422A1 (zh) | 抑制劑 | |
HK1213181A1 (zh) | 雙環氧雜內酰胺激酶抑制劑 | |
HK1209316A1 (zh) | 取代的吡啶酰胺激酶抑制劑 |